Thrombotic Complications Associated with Immune Checkpoint Inhibitors
Thromboembolism is a common complication in patients with cancer and is associated with significant morbidity and mortality. Anticancer treatment is a known risk factor of cancer-associated thrombosis. Immune checkpoint inhibitors have become a mainstay of treatment in various cancers. Both venous a...
Main Authors: | Tzu-Fei Wang, Alok A. Khorana, Marc Carrier |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-09-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/13/18/4606 |
Similar Items
-
Cancer‐associated venous thromboembolism: Treatment and prevention with rivaroxaban
by: Rupert Bauersachs, et al.
Published: (2020-05-01) -
Thromboembolic complications in nephrotic syndrome
by: Larisa A. Bobrova, et al.
Published: (2020-07-01) -
A review on superficial venous thrombosis of the lower extremities
by: Yung-Wei Chi, et al.
Published: (2019-01-01) -
Fondaparinux
by: G. Airoldi, et al.
Published: (2013-05-01) -
The Role of Direct Oral Anticoagulants in Cancer-Associated Thrombosis According to the Current Literature
by: Petroula Nana, et al.
Published: (2021-09-01)